ESMO Immuno-Oncology 2022 | PRADO: personalized response-driven therapy in resectable stage III melanoma

Irene Reijers, Netherlands Cancer Institute, Amsterdam, The Netherlands, provides an overview of the Phase II PRADO trial (NCT02977052), which assessed personalized treatment in patients with stage III melanoma based on major pathologic response (MPR) in the index lymph node. Neoadjuvant ipilimumab and nivolumab were initially administered, and patients who achieved a MPR then received follow-up, whereas patients with no response received a total lymph node dissection and adjuvant therapy. Partial and major response rates were consistent to those in the Phase II OpACIN-neo trial (NCT02977052) and omission of dissection in patients with MPR was deemed to be viable. This interview took place at the ESMO Immuno-Oncology Congress 2022 in Geneva, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.